Zevra Therapeutics, INC Form 4 insider transactions

Zevra Therapeutics, Inc. announced that Director Thomas Anderson was granted 30,000 stock options with an exercise price of $8.62 as compensation for his board service, aligning his interests with shareholder value.

Director Corey Michael Watton reports the acquisition and disposal of Zevra Therapeutics common stock on March 28, 2025.

Adrian W. Quartel, Chief Medical Officer of Zevra Therapeutics, was granted stock options and restricted stock units on January 30, 2025, according to a Form 4 filing.

Director John B. Bode of Zevra Therapeutics, Inc. purchased 10,000 shares of common stock at an average price of $7.9624 on March 19, 2025.

Timothy J. Sangiovanni, SVP of Finance & Corp Controller at Zevra Therapeutics, sold 3,000 shares of common stock at $7.8626 per share on February 13, 2025, under a pre-arranged 10b5-1 trading plan.

Joshua Schafer, CCO & EVP of Business Development at Zevra Therapeutics, sold 10,500 shares of common stock at a price of $7.8597 per share on February 13, 2025, according to a Form 4 filing with the SEC.

CFO & Treasurer of Zevra Therapeutics, R. LaDuane Clifton, sold 11,000 shares of common stock at $7.861 per share on February 13, 2025, according to a Form 4 filing.

Neil F. McFarlane, CEO of Zevra Therapeutics, sold shares of common stock on February 13th and 14th, 2025, under a pre-arranged 10b5-1 trading plan.

Neil F. McFarlane, CEO of Zevra Therapeutics, received stock options for 225,000 shares and 112,500 restricted stock units on February 7, 2025.

Timothy J. Sangiovanni, SVP, Finance & Corp Controller at Zevra Therapeutics, reports the vesting of restricted stock units and grant of stock options.

Rahsaan Thompson, Chief Legal & Compliance Secretary at Zevra Therapeutics, reports the acquisition of stock options and restricted stock units.

CCO & EVP of Business Development at Zevra Therapeutics, Joshua Schafer, reports the acquisition of stock options and vesting of restricted stock units.

R. LaDuane Clifton, CFO & Treasurer of Zevra Therapeutics, reports the acquisition of stock options and the vesting/settlement of restricted stock units.

Zevra Therapeutics CEO Neil F. McFarlane acquired 233,333 shares of common stock through the vesting of restricted stock units on January 31, 2025.

Director Corey Michael Watton reports acquisition and disposal of Zevra Therapeutics common stock on October 11, 2024.

R. LaDuane Clifton, CFO & Treasurer of Zevra Therapeutics, recently purchased 2,000 shares of the company's common stock at a price of $6.77 per share.

Director Thomas Anderson of Zevra Therapeutics reports purchasing $6.8065 worth of common stock and disposing of 20,000 shares.

Director John B. Bode of Zevra Therapeutics, Inc. [ZVRA] reported purchasing 10,000 shares of common stock at a weighted average price of $5.8661 on July 12, 2024, and disposing of 30,000 shares.

Rahsaan Thompson, Chief Legal & Compliance Secretary of Zevra Therapeutics, was granted 200,000 restricted stock units on June 21, 2024, under the company's 2023 Employment Inducement Award Plan.

Director John B. Bode acquired stock options in Zevra Therapeutics as part of director compensation.

Director Wendy L. Dixon received stock options for 39,200 shares of Zevra Therapeutics, Inc. at an exercise price of $4.89 on May 13, 2024, as compensation for board service.

Director Tamara A. Favorito received stock options for 49,200 shares of Zevra Therapeutics, Inc. at an exercise price of $4.89.

Director Douglas W. Calder received stock options for 39,200 shares of Zevra Therapeutics, Inc. as compensation for board service.

Director Corey Michael Watton received stock options for 39,200 shares of Zevra Therapeutics, Inc. at an exercise price of $4.89, as compensation for board service.

Director Alvin Shih received stock options for 39,200 shares of Zevra Therapeutics, Inc. at an exercise price of $4.89 on May 13, 2024, as compensation for board service.

Director Thomas Anderson received stock options for 39,200 shares of Zevra Therapeutics as compensation for board service.